www.imbruvica.com Open in urlscan Pro
2600:9000:2127:b400:1e:46ba:d300:93a1  Public Scan

Form analysis
0 forms found in the DOM

Text Content

Learn how AbbVie could help you save on IMBRUVICA®. Call 1-866-IMBRUVICA or
click to learn more >

Choose Indication
Affording IMBRUVICA®
Dosing Guide
Patient Support
& Savings
Financial Resources
Patient Resources
By Your Side Ambassadors
Patient Support Enrollment
Important Side
Effect Information
Prescribing Information
Full Prescribing Information (English)
Full Prescribing Information (En Español)
Español
Healthcare Professionals
CLL/SLL Home
What Is CLL/SLL?
Genetic Testing
IMBRUVICA® for CLL/SLL
How Does IMBRUVICA® Work?
Starting and Taking IMBRUVICA®
CLL/SLL Resources
Enroll for Updates
Patient Support & Savings


IMBRUVICA® HAS HELPED MANY ADULTS WITH CLL/SLL LIVE LONGER*

In a clinical trial of 269 people, 8% of CLL patients on IMBRUVICA® (ibrutinib)
died versus 16% taking a chemotherapy (chlorambucil), after 28 months of
follow-up.1*

Here’s to more time together and the opportunity to keep doing what you love.

Here's to the life in your years


HERE’S TO SAVING ON IMBRUVICA®

You may pay as little as $0 per prescription with the IMBRUVICA® Copay Card.
Subject to eligibility; restrictions apply.†

Enroll Now

Receive one-on-one support plus financial and educational resources to help
start and stay on track with IMBRUVICA®‡

Explore Support Options


UNDERSTANDING YOUR CLL DIAGNOSIS

Learn more about genetic testing and CLL

Learn More
About CLL/SLL



IMBRUVICA® FOR CLL

Questions to ask your doctor about CLL and IMBRUVICA®

Get More Information
About IMBRUVICA® for CLL



LEARN FROM A PATIENT

Real stories from CLL patients about their experience with IMBRUVICA®

View Patient
Videos Here


In one clinical trial of 269 people aged 65 and older with CLL or SLL who had
not been treated before, people who took IMBRUVICA® had a 56% lower risk of
death compared to those taking a chemotherapy (chlorambucil). With a median
follow-up of approximately 28 months, 8% of IMBRUVICA® patients died compared to
16% taking a chemotherapy.


WELCOME TO A DIFFERENT WAY OF TREATING CLL/SLL

Starting treatment is an important time in your journey with CLL/SLL. This
website will help you learn more about your condition and how IMBRUVICA® can
help.

IMBRUVICA® works differently from chemotherapy. This once-daily, oral medication
blocks a protein in B cells called Bruton's tyrosine kinase, or BTK. For more
complete information on how IMBRUVICA® works and the possible side effects, go
to the How Does IMBRUVICA® Work? section.1
 


WITH IMBRUVICA®, THERE’S A ONCE-DAILY ORAL TREATMENT OPTION AVAILABLE TO TREAT
CLL/SLL1


IMBRUVICA® is a prescription medicine used to treat adults with:

 * Chronic lymphocytic leukemia (CLL)/Small lymphocytic lymphoma (SLL)
 * Chronic lymphocytic leukemia (CLL)/Small lymphocytic lymphoma (SLL) with 17p
   deletion

It is not known if IMBRUVICA® is safe and effective in children.

Thinking about treatment with IMBRUVICA®?

Sign up today to receive the latest information and helpful resources.

Register Now

From the moment you’re prescribed IMBRUVICA®, IMBRUVICA® By Your Side provides
resources and support for getting the help you may need during treatment.*

Coverage and Cost

Confirm your coverage and out-of-pocket costs for IMBRUVICA®.

Support Communications

Receive periodic emails with tips and information about treatment.

IMBRUVICA® By Your Side Ambassadors*

Call a By Your Side Ambassador if you have questions about IMBRUVICA®.

Explore IMBRUVICA® By Your Side


†Eligible patients may pay as little as $0 per prescription of IMBRUVICA®. Rules
and maximum limits apply. Patients currently using the IMBRUVICA® Copay Card are
not eligible for retroactive billing or reimbursement of previous copays. The
IMBRUVICA® Copay Card is available to patients with commercial prescription
coverage for IMBRUVICA® who meet eligibility criteria. The IMBRUVICA® Copay Card
cannot be used by patients receiving prescription reimbursement under any
federal, state, or government-funded insurance programs, including Medicare Part
D, Medicare Advantage Plan, Medicaid, Medigap, VA, DOD, and TRICARE, or where
prohibited by law or the patient’s health insurance provider. The IMBRUVICA®
Copay program may be updated or discontinued at any time without notice.

‡IMBRUVICA® By Your Side patient support program is not intended to provide
medical advice, replace prescribed treatment plans, or provide treatment or case
management services. Patients are advised to talk to their healthcare provider
and treatment team about any medical decisions and concerns they may have. By
Your Side Ambassadors are provided by Janssen Biotech, Inc. and Pharmacyclics
LLC, an AbbVie Company, and do not work under the direction of your healthcare
professional (HCP) or give medical advice. They are trained to direct patients
to their HCP for treatment-related advice, including further referrals.

References: 1. IMBRUVICA® (ibrutinib) Prescribing Information. 2. National
Institutes of Health. BTK gene. Accessed June 6, 2023.
https://medlineplus.gov/genetics/gene/btk/



IMPORTANT SIDE EFFECT INFORMATION

USES

Before taking IMBRUVICA®, tell your healthcare provider about all of your
medical conditions, including if you:

 * have had recent surgery or plan to have surgery. Your healthcare provider may
   stop IMBRUVICA® for any planned medical, surgical, or dental procedure.
 * have bleeding problems
 * have or had heart rhythm problems, smoke, or have a medical condition that
   increases your risk of heart disease, such as high blood pressure, high
   cholesterol, or diabetes
 * have an infection
 * have liver problems
 * are pregnant or plan to become pregnant. IMBRUVICA® can harm your unborn
   baby. If you are able to become pregnant, your healthcare provider will do a
   pregnancy test before starting treatment with IMBRUVICA®. Tell your
   healthcare provider if you are pregnant or think you may be pregnant during
   treatment with IMBRUVICA®.
   * Females who are able to become pregnant should use effective birth control
     (contraception) during treatment with IMBRUVICA® and for 1 month after the
     last dose.
   * Males with female partners who are able to become pregnant should use
     effective birth control, such as condoms, during treatment with IMBRUVICA®
     and for 1 month after the last dose.
 * are breastfeeding or plan to breastfeed. Do not breastfeed during treatment
   with IMBRUVICA® and for 1 week after the last dose. 

Tell your healthcare provider about all the medicines you take, including
prescription and over-the-counter medicines, vitamins, and herbal supplements.
Taking IMBRUVICA® with certain other medicines may affect how IMBRUVICA® works
and can cause side effects.

How should I take IMBRUVICA®?

 * Take IMBRUVICA® exactly as your healthcare provider tells you to take it.
 * Take IMBRUVICA® 1 time a day at about the same time each day.

IMBRUVICA® comes as capsules, tablets, and oral suspension.

 * If your healthcare provider prescribes IMBRUVICA® capsules or tablets:
   * Swallow IMBRUVICA® capsules or tablets whole with a glass of water.
   * Do not open, break, or chew IMBRUVICA® capsules.
   * Do not cut, crush, or chew IMBRUVICA® tablets.
 * If your healthcare provider prescribes IMBRUVICA® oral suspension:
   * See the detailed Instructions for Use that comes with IMBRUVICA® oral
     suspension for information about the correct way to give a dose to your
     child. If you have questions about how to give IMBRUVICA® oral suspension,
     talk to your healthcare provider.
   * Do not use if the carton seal is broken or missing.
 * If you miss a dose of IMBRUVICA® take it as soon as you remember on the same
   day. Take your next dose of IMBRUVICA® at your regular time on the next day.
   Do not take extra doses of IMBRUVICA® to make up for a missed dose.
 * If you take too much IMBRUVICA® call your healthcare provider or go to the
   nearest hospital emergency room right away. 

What should I avoid while taking IMBRUVICA®?

 * You should not drink grapefruit juice, eat grapefruit, or eat Seville oranges
   (often used in marmalades) during treatment with IMBRUVICA®. These products
   may increase the amount of IMBRUVICA® in your blood.

What are the possible side effects of IMBRUVICA®?

IMBRUVICA® may cause serious side effects, including:

 * Bleeding problems (hemorrhage) are common during treatment with IMBRUVICA®,
   and can also be serious and may lead to death. Your risk of bleeding may
   increase if you are also taking a blood thinner medicine. Tell your
   healthcare provider if you have any signs of bleeding, including: blood in
   your stools or black stools (looks like tar), pink or brown urine, unexpected
   bleeding, or bleeding that is severe or that you cannot control, vomit blood
   or vomit looks like coffee grounds, cough up blood or blood clots, increased
   bruising, dizziness, weakness, confusion, change in your speech, or a
   headache that lasts a long time or severe headache.  
 * Infections can happen during treatment with IMBRUVICA®. These infections can
   be serious and may lead to death. Tell your healthcare provider right away if
   you have fever, chills, weakness, confusion, or other signs or symptoms of an
   infection during treatment with IMBRUVICA®.
 * Heart problems. Serious heart rhythm problems (ventricular arrhythmias,
   atrial fibrillation and atrial flutter), heart failure and death have
   happened in people treated with IMBRUVICA®, especially in people who have an
   infection, an increased risk for heart disease, or have had heart rhythm
   problems in the past. Your heart function will be checked before and during
   treatment with IMBRUVICA®. Tell your healthcare provider if you get any
   symptoms of heart problems, such as feeling as if your heart is beating fast
   and irregular, lightheadedness, dizziness, shortness of breath, swelling of
   the feet, ankles or legs, chest discomfort, or you faint. If you develop any
   of these symptoms, your healthcare provider may do tests to check your heart
   and may change your IMBRUVICA® dose.
 * High blood pressure (hypertension). New or worsening high blood pressure has
   happened in people treated with IMBRUVICA®. Your healthcare provider may
   start you on blood pressure medicine or change current medicines to treat
   your blood pressure.
 * Decrease in blood cell counts. Decreased blood counts (white blood cells,
   platelets, and red blood cells) are common with IMBRUVICA®, but can also be
   severe. Your healthcare provider should do monthly blood tests to check your
   blood counts.
 * Second primary cancers. New cancers have happened during treatment with
   IMBRUVICA®, including cancers of the skin or other organs.
 * Tumor lysis syndrome (TLS). TLS is caused by the fast breakdown of cancer
   cells. TLS can cause kidney failure and the need for dialysis treatment,
   abnormal heart rhythm, seizure, and sometimes death. Your healthcare provider
   may do blood tests to check you for TLS.

The most common side effects of IMBRUVICA® in adults with B-cell malignancies
(CLL/SLL and WM) include:

 * diarrhea
 * tiredness
 * muscle and bone pain

 * rash
 * bruising
 * nausea

The most common side effects of IMBRUVICA® in adults or children 1 year of age
and older with cGVHD include:

 * tiredness
 * low red blood cell count (anemia)
 * bruising
 * diarrhea
 * low platelet count

 * muscle and joint pain
 * fever
 * muscle spasms
 * mouth sores (stomatitis)
 * bleeding

 * nausea
 * stomach pain
 * pneumonia
 * headache

Diarrhea is a common side effect in people who take IMBRUVICA®. Drink plenty of
fluids during treatment with IMBRUVICA® to help reduce your risk of losing too
much fluid (dehydration) due to diarrhea. Tell your healthcare provider if you
have diarrhea that does not go away.

These are not all the possible side effects of IMBRUVICA®. Call your doctor for
medical advice about side effects. You may report side effects to FDA at
1-800-FDA-1088.

General information about the safe and effective use of IMBRUVICA®

Medicines are sometimes prescribed for purposes other than those listed in a
Patient Information leaflet. Do not use IMBRUVICA® for a condition for which it
was not prescribed. Do not give IMBRUVICA® to other people, even if they have
the same symptoms that you have. It may harm them. You can ask your pharmacist
or healthcare provider for information about IMBRUVICA® that is written for
health professionals.

Please see the full Important Product Information.

USES

What is IMBRUVICA® (ibrutinib)?

IMBRUVICA® (ibrutinib) is a prescription medicine used to treat:

 * Adults with chronic lymphocytic leukemia (CLL)/Small lymphocytic lymphoma
   (SLL).
 * Adults with chronic lymphocytic leukemia (CLL)/Small lymphocytic lymphoma
   (SLL) with 17p deletion.
 * Adults with Waldenström's macroglobulinemia (WM).
 * Adults and children 1 year of age and older with chronic graft versus host
   disease (cGVHD) after failure of 1 or more lines of systemic therapy.

It is not known if IMBRUVICA® is safe and effective in children under 1 year of
age.

Please see the full Important Product Information.

Pharmacyclics, an AbbVie Company, may collect your personal data through your
online and offline interactions with us, including your contact, demographic,
geolocation, and health-related data. We may also collect your online usage data
automatically through cookies and similar technologies. We use this data for
several purposes, such as to provide you with and improve our programs,
services, and products, customize your experiences, and for research and
analytics. We retain your personal data for as long as necessary to fulfill
these purposes or to comply with our record retention obligations. We do not
sell your personal data but may use and disclose your personal data with
marketing and advertising partners to deliver you ads based on your interests
inferred from your activity across other unaffiliated sites and services
(“online targeted advertising”) and for website analytics. To opt out of the use
or disclosure of your personal data for online targeted advertising or for
website analytics, go to Your Privacy Choices on our website. For more
information on the personal data categories we collect, the purposes for their
collection, our disclosures to third parties, your data subject rights, and our
data retention criteria, visit our Privacy Notice.

Through my submission of the program enrollment form, I consent to the
collection, use, and disclosure of my personal health data, as described in the
Privacy Notice above and in AbbVie’s Privacy Notice in the How We May Disclose
Personal Data section. My consent is required to process sensitive personal data
under certain privacy laws, and I have the right to withdraw my consent by
visiting Your Privacy Choices on AbbVie’s website.

IMBRUVICA® (ibrutinib) is covered by U.S. Patents, which are listed in FDA's
Orange Book (available at
https://www.accessdata.fda.gov/scripts/cder/ob/default.cfm).

© Pharmacyclics LLC 2023

© Janssen Biotech, Inc. 2023

09/23 PRC-10335


 * Home
 * Prescribing Information
 * Important Side Effect Information
 * Legal Notice
 * Privacy Notice
 * Accessibility Statement
 * Cookie Settings
 * Your Privacy Choices
 * Contact Us
 * Site Map






This site uses online tracking technologies such as cookies to personalize
content, save your preferences, provide social media features, enable
personalized advertising and track the site’s performance as described in our
Privacy Notice. Please click on Cookies Settings below to manage your
preferences.


Cookies Settings



PRIVACY PREFERENCE CENTER

When you visit any website, it may store or retrieve information on your
browser, mostly in the form of cookies. This information might be about you,
your preferences or your device and is mostly used to make the site work as you
expect it to. The information does not usually directly identify you, but it can
give you a more personalized web experience.

You can choose not to allow some types of cookies. Click on the different
category headings to find out more and change our default settings. However,
blocking some types of cookies may impact your experience of the site and the
services we are able to offer.
More information


MANAGE CONSENT PREFERENCES

REQUIRED COOKIES

Always Active

These cookies are necessary for the website to function and cannot be switched
off in our systems. They may be set by us or by third party providers whose
services we have added to our pages. They are usually only set in response to
actions made by you which amount to a request for services, such as setting your
privacy preferences, logging in or filling in forms. You can set your browser to
block or alert you about these cookies, but some parts of the site will not then
work.

View Vendor Details‎

FUNCTIONAL COOKIES

Always Active

These cookies allow us to count visits and traffic sources so we can measure and
improve the performance of our site. They may be set by us or by third party
providers whose services we have added to our pages. They help us to know which
pages are the most and least popular and see how visitors move around the site.

View Vendor Details‎

ADVERTISING COOKIES

Advertising Cookies

These cookies may be set through our site by our advertising partners to build a
profile of your interests and show you relevant adverts on other sites. They do
not store directly personal information but are based on uniquely identifying
your browser and internet device. If you do not allow these cookies, you will
experience less targeted advertising, but you will still receive online
advertising.

View Vendor Details‎
Back Button


VENDORS LIST



Search Icon
Filter Icon

Clear
checkbox label label
Apply Cancel
Consent Leg.Interest
checkbox label label
checkbox label label
checkbox label label

 * 
   
   View Cookies
   
    * Name
      cookie name

Confirm My Choices